Literature DB >> 18760506

Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin.

David F Fischer1, Renske van Dijk, Paula van Tijn, Barbara Hobo, Marian C Verhage, Roel C van der Schors, Ka Wan Li, Jan van Minnen, Elly M Hol, Fred W van Leeuwen.   

Abstract

Many neurodegenerative diseases are characterized by deposits of ubiquitinated and aberrant proteins, suggesting a failure of the ubiquitin-proteasome system (UPS). The aberrant ubiquitin UBB(+1) is one of the ubiquitinated proteins accumulating in tauopathies such as Alzheimer's disease (AD) and polyglutamine diseases such as Huntington's disease. We have generated UBB(+1) transgenic mouse lines with post-natal neuronal expression of UBB(+1), resulting in increased levels of ubiquitinated proteins in the cortex. Moreover, by proteomic analysis, we identified expression changes in proteins involved in energy metabolism or organization of the cytoskeleton. These changes show a striking resemblance to the proteomic profiles of both AD brain and several AD mouse models. Moreover, UBB(+1) transgenic mice show a deficit in contextual memory in both water maze and fear conditioning paradigms. Although UBB(+1) partially inhibits the UPS in the cortex, these mice do not have an overt neurological phenotype. These mouse models do not replicate the full spectrum of AD-related changes, yet provide a tool to understand how the UPS is involved in AD pathological changes and in memory formation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18760506     DOI: 10.1016/j.neurobiolaging.2008.06.009

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  27 in total

Review 1.  The ubiquitin-proteasome pathway and synaptic plasticity.

Authors:  Ashok N Hegde
Journal:  Learn Mem       Date:  2010-06-21       Impact factor: 2.460

Review 2.  Neural mechanisms of ageing and cognitive decline.

Authors:  Nicholas A Bishop; Tao Lu; Bruce A Yankner
Journal:  Nature       Date:  2010-03-25       Impact factor: 49.962

Review 3.  Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications.

Authors:  Qian Huang; Maria E Figueiredo-Pereira
Journal:  Apoptosis       Date:  2010-11       Impact factor: 4.677

Review 4.  Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease.

Authors:  Ashok N Hegde; Sudarshan C Upadhya
Journal:  Biochim Biophys Acta       Date:  2010-08-03

Review 5.  Ubiquitylation at the crossroads of development and disease.

Authors:  Michael Rape
Journal:  Nat Rev Mol Cell Biol       Date:  2017-09-20       Impact factor: 94.444

6.  The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease.

Authors:  Yasuo Ihara; Maho Morishima-Kawashima; Ralph Nixon
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

Review 7.  Proteolysis, synaptic plasticity and memory.

Authors:  Ashok N Hegde
Journal:  Neurobiol Learn Mem       Date:  2016-09-07       Impact factor: 2.877

8.  Long-term proteasomal inhibition in transgenic mice by UBB(+1) expression results in dysfunction of central respiration control reminiscent of brainstem neuropathology in Alzheimer patients.

Authors:  Martin Irmler; Romina J G Gentier; Frank J A Dennissen; Holger Schulz; Ines Bolle; Sabine M Hölter; Magdalena Kallnik; Jing Jun Cheng; Martin Klingenspor; Jan Rozman; Nicole Ehrhardt; Denise J H P Hermes; Valérie Gailus-Durner; Helmut Fuchs; Martin Hrabě de Angelis; Helmut E Meyer; David A Hopkins; Fred W Van Leeuwen; Johannes Beckers
Journal:  Acta Neuropathol       Date:  2012-06-23       Impact factor: 17.088

9.  Disease-associated mutant ubiquitin causes proteasomal impairment and enhances the toxicity of protein aggregates.

Authors:  Elizabeth M H Tank; Heather L True
Journal:  PLoS Genet       Date:  2009-02-13       Impact factor: 5.917

Review 10.  Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases.

Authors:  Baohua Liu; Jing Ruan; Meng Chen; Zhongding Li; Gloria Manjengwa; Dirk Schlüter; Weihong Song; Xu Wang
Journal:  Mol Psychiatry       Date:  2021-07-20       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.